Hirtle Callaghan & Co’s Chemours CC Stock Holding History

Hirtle Callaghan & Co’s Portfolio CC Stock Details CC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,080	Closed	-$53K	–	109
2018 Q1	$53K	Hold	1,080	–	–	﹤0.01%	94
2017 Q4	$54K	Hold	1,080	–	–	0.01%	103
2017 Q3	$55K	Buy	+1,080	New	+$51K	0.01%	100
2016 Q4	–	Sell	-1,080	Closed	-$17K	–	158
2016 Q3	$17K	Hold	1,080	–	–	﹤0.01%	177
2016 Q2	$9K	Hold	1,080	–	–	﹤0.01%	162
2016 Q1	$8K	Buy	+1,080	New	+$5.43K	﹤0.01%	163

Other funds holding CC

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Hirtle Callaghan & Co's CC Position: Q2 2018 in Review

Hirtle Callaghan & Co sold out of Chemours (CC) in Q2 2018, closing a stake of 1,080 shares — an estimated $53K sold.

Hirtle Callaghan & Co first reported a position in CC in Q1 2016 and held it in 6 quarters. The position peaked at $55K in Q3 2017. 558 funds tracked by Wall St. Rank hold CC as of Q2 2018.

Hirtle Callaghan & Co reported no remaining Chemours position as of Q2 2018 after selling out during the quarter.
Hirtle Callaghan & Co sold 1,080 Chemours shares in Q2 2018, an estimated $53K.
Hirtle Callaghan & Co first reported a position in Chemours in Q1 2016 and held it in 6 quarters.
Hirtle Callaghan & Co's Chemours position peaked at $55K in Q3 2017.
558 funds tracked by Wall St. Rank held Chemours as of Q2 2018.

Based on Hirtle Callaghan & Co's 13F filing for Q2 2018, filed 23 Jul 2018.